108 related articles for article (PubMed ID: 25467152)
1. Design, synthesis, and evaluation of a selective chemosensor for leucine-rich repeat kinase 2.
Szalewski DA; Beck JR; Stains CI
Bioorg Med Chem Lett; 2014 Dec; 24(24):5648-5651. PubMed ID: 25467152
[TBL] [Abstract][Full Text] [Related]
2. A continuous and direct assay to monitor leucine-rich repeat kinase 2 activity.
Silva RG; Geoghegan KF; Qiu X; Aulabaugh A
Anal Biochem; 2014 Apr; 450():63-9. PubMed ID: 24463014
[TBL] [Abstract][Full Text] [Related]
3. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease.
Nichols RJ; Dzamko N; Hutti JE; Cantley LC; Deak M; Moran J; Bamborough P; Reith AD; Alessi DR
Biochem J; 2009 Oct; 424(1):47-60. PubMed ID: 19740074
[TBL] [Abstract][Full Text] [Related]
4. Design and evaluation of a real-time activity probe for focal adhesion kinase.
Beck JR; Zhou X; Casey GR; Stains CI
Anal Chim Acta; 2015 Oct; 897():62-8. PubMed ID: 26515006
[TBL] [Abstract][Full Text] [Related]
5. A real-time, fluorescence-based assay for Rho-associated protein kinase activity.
Kelly MI; Bechtel TJ; Reddy DR; Hankore ED; Beck JR; Stains CI
Anal Chim Acta; 2015 Sep; 891():284-90. PubMed ID: 26388388
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of LRRK2: from kinase to substrate.
Lobbestael E; Baekelandt V; Taymans JM
Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
[TBL] [Abstract][Full Text] [Related]
7. Identification of the autophosphorylation sites of LRRK2.
Kamikawaji S; Ito G; Iwatsubo T
Biochemistry; 2009 Nov; 48(46):10963-75. PubMed ID: 19824698
[TBL] [Abstract][Full Text] [Related]
8. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.
Galatsis P; Henderson JL; Kormos BL; Han S; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD
Bioorg Med Chem Lett; 2014 Sep; 24(17):4132-40. PubMed ID: 25113930
[TBL] [Abstract][Full Text] [Related]
9. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
Deng X; Choi HG; Buhrlage SJ; Gray NS
Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
[TBL] [Abstract][Full Text] [Related]
10. Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.
Hamm M; Bailey R; Shaw G; Yen SH; Lewis J; Giasson BI
J Neurosci Res; 2015 Oct; 93(10):1567-80. PubMed ID: 26123245
[TBL] [Abstract][Full Text] [Related]
11. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
[TBL] [Abstract][Full Text] [Related]
12. Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors.
Liu M; Poulose S; Schuman E; Zaitsev AD; Dobson B; Auerbach K; Seyb K; Cuny GD; Glicksman MA; Stein RL; Yue Z
Anal Biochem; 2010 Sep; 404(2):186-92. PubMed ID: 20566370
[TBL] [Abstract][Full Text] [Related]
13. Development of a high-throughput AlphaScreen assay measuring full-length LRRK2(G2019S) kinase activity using moesin protein substrate.
Pedro L; Padrós J; Beaudet L; Schubert HD; Gillardon F; Dahan S
Anal Biochem; 2010 Sep; 404(1):45-51. PubMed ID: 20434426
[TBL] [Abstract][Full Text] [Related]
14. Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays.
Anand VS; Reichling LJ; Lipinski K; Stochaj W; Duan W; Kelleher K; Pungaliya P; Brown EL; Reinhart PH; Somberg R; Hirst WD; Riddle SM; Braithwaite SP
FEBS J; 2009 Jan; 276(2):466-78. PubMed ID: 19076219
[TBL] [Abstract][Full Text] [Related]
15. Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease?
Taymans JM
Expert Opin Ther Pat; 2014 Jul; 24(7):727-30. PubMed ID: 24875782
[TBL] [Abstract][Full Text] [Related]
16. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein.
Yun H; Heo HY; Kim HH; DooKim N; Seol W
Bioorg Med Chem Lett; 2011 May; 21(10):2953-7. PubMed ID: 21474311
[TBL] [Abstract][Full Text] [Related]
17. Pyrazolopyridines as inhibitors of the kinase LRRK2: a patent evaluation (WO2011141756).
Deng X; S Gray N
Expert Opin Ther Pat; 2012 Jun; 22(6):709-13. PubMed ID: 22607035
[TBL] [Abstract][Full Text] [Related]
18. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.
Guo L; Gandhi PN; Wang W; Petersen RB; Wilson-Delfosse AL; Chen SG
Exp Cell Res; 2007 Oct; 313(16):3658-70. PubMed ID: 17706965
[TBL] [Abstract][Full Text] [Related]
19. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
20. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?
Gillardon F; Kremmer E; Froehlich T; Ueffing M; Hengerer B; Gloeckner CJ
J Neurosci Methods; 2013 Mar; 214(1):62-8. PubMed ID: 23318290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
